Showing results (171-180 of 553) with videos related to
Sort By:
Pageof 56
Physics in Medicine and Biology|July 1, 1978
A comparison of optimum detector spatial resolution in nuclear imaging based on statistical theory and on observer performanceB M Tsui, C E Metz, F B Atkins, et al.JCO Oncology Practice|December 1, 2023
Systemic Therapy for Melanoma: ASCO Guideline Update Q and AVernon K Sondak, Michael B Atkins, Hans Messersmith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684B E Hillner, J M Kirkwood, M B Atkins, et al.Critical Care Medicine|November 1, 1995
Effects of malignancy and interleukin-2 infusion on gut macromolecular permeabilityC M Ryan, M B Atkins, J W Mier, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1993
Possible myocardial toxicity associated with interleukin-4 therapyE G Trehu, J M Isner, J W Mier, et al.The Journal of Biological Chemistry|March 28, 2018
Myeloperoxidase-derived oxidants damage artery wall proteins in an animal model of chronic kidney disease-accelerated atherosclerosisLixia Zeng, Anna V Mathew, Jaeman Byun, et al.Journal of Medical Economics|October 13, 2012
Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysisVictor Barzey, Michael B Atkins, Louis P Garrison, et al.Urologic Oncology|November 13, 2012
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)Toni K Choueiri, Suchun Cheng, Angela Q Qu, et al.Clinical Genitourinary Cancer|February 14, 2009
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinomaKathryn A Bylow, Michael B Atkins, Edwin M Posadas, et al.The Journal of Pharmacology and Experimental Therapeutics|September 11, 2003
Acetylcholinesterase inhibitors activate septohippocampal GABAergic neurons via muscarinic but not nicotinic receptorsMin Wu, Samuel S Newton, Joshua B Atkins, et al.Pageof 56